In vitro antitumor effects of FGFR and PI3K inhibitors on human papillomavirus positive and negative tonsillar and base of tongue cancer cell lines

  • Authors:
    • Stefan Holzhauser
    • Ourania N. Kostopoulou
    • Anna Ohmayer
    • Birthe K.A. Lange
    • Torbjörn Ramqvist
    • Teodora Andonova
    • Cinzia Bersani
    • Malin Wickström
    • Tina Dalianis
  • View Affiliations

  • Published online on: October 9, 2019     https://doi.org/10.3892/ol.2019.10973
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Human papillomavirus positive (HPV+) tonsillar and base of tongue squamous cell carcinoma (TSCC/BOTSCC) have better outcomes than corresponding HPV‑ negative (HPV‑) cancer cases. Our previous study demonstrated that fibroblast growth factor receptor 3 (FGFR3) and phosphatidylinositol‑4,5‑bisphosphate 3‑kinase catalytic subunit a (PIK3CA) are often mutated in HPV+ cancer. To investigate whether targeted therapy is an option for TSCC/BOTSCC, two HPV+ and one HPV‑ TSCC/BOTSCC cell lines were tested for their sensitivity towards FGFR and PI3K inhibitors. The HPV+ cell lines UM‑SCC‑47 and UPCI‑SCC‑154, and the HPV‑ cell line UT‑SSC‑60A were tested by competitive allele‑specific TaqMan‑PCR for presence/absence of frequently occurring FGFR3 and PIK3CA mutations. All cells were then treated with FGFR inhibitor AZD4547 and PI3K inhibitors BEZ235 and BKM120 alone, or with AZD4547 and BEZ235 in combination. Viability was analyzed using a WST‑1 assay, cytotoxicity tested by a CellTox Green cytotoxicity assay, apoptosis analyzed by a Caspase Glo 3/7 assay and proliferation examined with the xCELLigence system. HPV+ UM‑SCC‑47 and UPCI‑SCC‑154 cells, and HPV‑ UT‑SSC‑60A cells, did not exhibit any common FGFR3 or PIK3CA mutations, but were all sensitive to FGFR inhibitor AZD4547 and PI3K inhibitors BEZ235 and BKM120. Notably, HPV+ UPCI‑SCC‑154 cells were more sensitive than the other two cell lines. Furthermore, when AZD4547 and BEZ235 treatment was combined in HPV+ UPCI‑SCC‑154 and HPV‑ UT‑SSC‑60A cells, potentiated combination effects were observed. HPV+ UM‑SCC‑47 and UPCI‑SCC‑154 cells, and HPV‑ UT‑SSC‑60A cells had no common FGFR3 or PIK3CA mutations, but were sensitive to FGFR inhibitor AZD4547, and PI3K inhibitors BEZ235 and BKM120. Furthermore, the latter two cell lines were particularly sensitive to combinations of AZD4547 and BEZ235.

Related Articles

Journal Cover

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Holzhauser, S., Kostopoulou, O.N., Ohmayer, A., Lange, B.K., Ramqvist, T., Andonova, T. ... Dalianis, T. (1899). In vitro antitumor effects of FGFR and PI3K inhibitors on human papillomavirus positive and negative tonsillar and base of tongue cancer cell lines. Oncology Letters, 0, 0-0. https://doi.org/10.3892/ol.2019.10973
MLA
Holzhauser, S., Kostopoulou, O. N., Ohmayer, A., Lange, B. K., Ramqvist, T., Andonova, T., Bersani, C., Wickström, M., Dalianis, T."In vitro antitumor effects of FGFR and PI3K inhibitors on human papillomavirus positive and negative tonsillar and base of tongue cancer cell lines". Oncology Letters 0.0 (1899): 0-0.
Chicago
Holzhauser, S., Kostopoulou, O. N., Ohmayer, A., Lange, B. K., Ramqvist, T., Andonova, T., Bersani, C., Wickström, M., Dalianis, T."In vitro antitumor effects of FGFR and PI3K inhibitors on human papillomavirus positive and negative tonsillar and base of tongue cancer cell lines". Oncology Letters 0, no. 0 (1899): 0-0. https://doi.org/10.3892/ol.2019.10973